We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer, Valneva Launch Phase 2 Trial for Lyme Disease Vaccine
Pfizer, Valneva Launch Phase 2 Trial for Lyme Disease Vaccine
Pfizer and French drugmaker Valneva have initiated a new phase 2 study evaluating VLA15, their experimental vaccine for Lyme disease — and say this is likely to be the last one before the candidate progresses to phase 3 trials.